Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue
Mumbai, June 10, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic cases, with no important safety risks identified, in the…
Read More...
Read More...